Briacell Therapeutics Corp · TSX:BCT
Briacell Therapeutics — Investor Presentation (September 2026)
27 slides from Briacell Therapeutics's investor presentation, Sep 28, 2026
Slide 1: Investor Presentation Autumn 2026
Nasdaq: BCTX, BCTXL, BCTXZ INVESTOR PRESENTATION TSX: BCT Autumn 2026 Developing Novel Therapeutics to Destroy Cancer
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) solely for information purposes. This presentation is not intended to provide the basis of any credit or other evaluation, does not constitute an offer or invitation to sell or issue, or solic
Slide 3: Forward Looking Statements
Forward Looking Statements The Company makes certain filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission (the “SEC”), all of which are available under our profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. For a more complete d
Slide 4: BriaCell: Novel Immunotherapies to Fight Cancer
BriaCell: Novel Immunotherapies to Fight Cancer ▪ Clinical stage immuno-oncology company developing an entirely new class of targeted immunotherapies to transform cancer care ▪ Lead drug candidate Bria-IMT ➢ Pivotal Phase 3 study underway in metastatic breast cancer (over 40K US deaths/year) ➢ Phase
Slide 5: Bria-IMT: Lead Candidate
Bria-IMT: Lead Candidate ▪ Bria-IMT - a cell based, patented, targeted immunotherapy ▪ Derived from a well characterized breast cancer cell line ▪ Expresses tumor antigens and GM-CSF to activate cancer fighting CD4+ and CD8+ T cells ▪ Stimulates the immune system to enhance targeted killing of cance
Slide 6: Bria-IMT Monotherapy Phase 2 Clinical Data
Bria-IMT Monotherapy Phase 2 Clinical Data Disease Control Disease Control in Immune Evaluable Patients HLA Match (CR, PR, and SD) Responders (DTH) N=5 ≥2 80% (4/5) 100% (4/4) N=18 Any 50% (9/18) 60% (9/15) ▪ 27 total heavily pre-treated (median 5 prior regimens) metastatic breast cancer patients tr
Slide 7: Bria-IMT Combination with CPIs
Bria-IMT Combination with CPIs How Do CPIs Work? ▪ PD-L1 expression protects cancer cells from tumor antigen driven T-cell attack ▪ PD-1 and PD-L1 inhibitors, also known as CPIs, neutralize this immune suppression Why combine Bria-IMT with CPIs? ▪ >90% of patients express PD-L1 in our studies ▪ Pote
Slide 8: Bria-IMT + CPI Phase 2 Study
Bria-IMT + CPI Phase 2 Study 100 ▪ Total of 54 patients enrolled ➢ 11 treated in combination with pembrolizumab ➢ 44 treated in combination with retifanlimab Progression Free Survival (%) Phase 3 Formulation (n=37) ➢ one cross-over 75 Median PFS 3.6 months ▪ Median 6 prior regimens Formulation with
Slide 9: Bria-IMT + CPI Overall Survival in Randomized Phase 2
Bria-IMT + CPI Overall Survival in Randomized Phase 2 Overall Survival by Sequence and Formulation ▪ 32 patients treated with 2 sequences 100 CPI at C2 Median OS = 7.4 months ➢ 16 patients CPI in Cycle 1 (Phase 3 Sequence) Phase 3 Sequence Median OS = 13.3 months ➢ A subset also received the Phase 3
Slide 10: Bria-IMT + CPI Phase 2 OS vs Trodelvy in HR+ MBC
Bria-IMT + CPI Phase 2 OS vs Trodelvy in HR+ MBC ▪ 37 patients treated with Phase 3 Overall survival of Bria-IMT vs TROPiCS-022 formulation ➢ Median 6 prior lines of therapy ➢ 24 patients hormone receptor (HR+) ➢ Overall survival (OS) 13.4 months for HR+ Patients ➢ OS 14.3 months for HR+ Patients tr
Slide 11: Bria-IMT + CPI Phase 2 OS vs Trodelvy in TNBC
Bria-IMT + CPI Phase 2 OS vs Trodelvy in TNBC ▪ 37 patients treated with Phase 3 Overall survival of Bria-IMT vs ASCENT1 formulation ➢ Median 6 prior lines of therapy ➢ 10 patients with triple-negative breast Bria-IMT TNBC Ph 3 Formulation Bria-IMT TNBC Ph 3 Formulation p2022 cancer (TNBC) ASCENT Tr
Slide 12: Comparison to Other Similar ADC Resistant Patients
Comparison to Other Similar ADC Resistant Patients ▪ ~4 months median progression-free survival (PFS) twice that seen in comparable patients treated with best available therapy, including antibody-drug conjugate (ADC) resistant patients1,2,3 ▪ Clinical benefit seen in 53% of evaluable patients in al
Slide 13: Robust Market Potential
Robust Market Potential Prior PFS WW 2025 Drug Trial Lines ORR (%) (months) Sales* (Bil $) Bria-IMT™ Ph 2 5.5 10 3.6 ~$2.5 billion Bria-IMT KISQALI® (ribociclib) Ph 1/2a (MBC previously Rx trastuzumab, pertuzumab, and trastuzumab emtansine)1 5 0 1.3 $ 4.8 opportunity# KEYTRUDA® ** Ph 2 1 0 1.9 $ 31.
Slide 14: Bria-IMT + CPI Remarkable CNS Responder Case #1
Bria-IMT + CPI Remarkable CNS Responder Case #1 Baseline Scans On Treatment Scans ▪ Patient on 13 prior failed regimens ▪ Baseline breast cancer metastases ➢ Behind the left eye (orbit) ➢ Outside lining of the brain (dura mater) ➢ Adrenal gland ▪ 6 months of treatment ➢ Orbital tumor completely reso
Slide 15: Bria-IMT + CPI Remarkable CNS Responder Case #2
Bria-IMT + CPI Remarkable CNS Responder Case #2 Orbital tumor with proptosis ▪ Patient on 8 prior failed regimens including ADC Enhertu® ▪ Baseline tumor status ➢ Extensive proptosis (eye bulging) & brain (temporal lobe) metastasis ▪ Marked tumor reduction at 11 months ➢ Near complete proptosis reso
Slide 16: Impressive CNS Response Rate in MBC Patients
Impressive CNS Response Rate in MBC Patients Intracranial Tumor Responses* ▪ 71% (5/7) intracranial objective response rate (iORR) ➢ Positive results in both Bria-IMT monotherapy and CPI combination 50 Monotherapy + Pembrolizumab ▪ iORR in comparable patients typically <20%1,2 +Retifanlimab ▪ Respon
Slide 17: Bria-IMT + CPI Pivotal Phase 3 Study
Bria-IMT + CPI Pivotal Phase 3 Study ▪ Ongoing pivotal Phase 3 study in Advanced Breast Cancer (Bria-ABC) ▪ Primary endpoint of overall survival ➢ Interim efficacy at 144 events ➢ 97.5% powered to detect a 40% reduction in mortality ▪ Positive interim results could support FULL approval of Bria-IMT
Slide 18: BriaCell Featured in Nature Medicine
BriaCell Featured in Nature Medicine Nature Medicine | Volume 31 | December 2025 | 3943–3947 | 3943 ▪ Currently over 75 clinical sites open in the US for the Phase 3 study including Mayo Clinic, U of Arizona, Cedar-Sinai, UCLA, UC San Diego, Yale, U Miami, Northwestern, Dartmouth, Cleveland Clinic,
Slide 19: Bria-OTS Personalized & Off-The-Shelf
Bria-OTS Personalized & Off-The-Shelf ▪ BriaCell immunotherapy is most effective in human leukocyte antigen (HLA) type matched patients ▪ HLA typing identifies patient specific immune cells presenting antigens necessary for immune response ▪ Bria-OTS expresses 15 HLA types in 4 cell lines, providing
Slide 20: Bria-OTS Metastatic Breast Cancer Phase 1/2a
Bria-OTS Metastatic Breast Cancer Phase 1/2a ▪ Initial monotherapy dose escalation then dose expansion in combination with CPI ➢ Up to 18 patients including 9 patient dose expansion ▪ Results of first patient treated: ➢ Complete resolution of lung lesion at two months sustained for 11 months ➢ Stabl
Slide 21: From Bria-IMT to Bria-OTS to Bria-OTS+
From Bria-IMT to Bria-OTS to Bria-OTS+: Engineering Stronger, Broader Immune Activation Bria-IMT (1st Generation) ❑ Breast cancer cell line engineered to express GM-CSF ❑ Demonstrated clinical activity and survival benefit in Phase 1/2a ❑ Validates whole-cell immunotherapy and provides the foundatio
Slide 22: Expected Development Timeline and Catalysts
Expected Development Timeline and Catalysts Bria-IMT + CPI • Presentations at scientific conferences • Quarterly DSMB updates on pivotal Phase 3 study Phase 3 interim analysis Potential marketing in 2026 & BLA submission approval 2H 2026 1H 2027 2H 2027 1H 2028 2H 2028 Bria-OTS/OTS+ • OTS Phase 1/2a
Slide 23: Experienced Management
Experienced Management William V. Williams, MD, FACP Giuseppe Del Priore, MD, MPH President & CEO, Director Chief Medical Officer ▪ Incyte, GlaxoSmithKline ▪ Cancer Treatment Centers of America ▪ University of Pennsylvania ▪ NYU School of Medicine, New York Presbyterian Gadi Levin, CA, MBA Miguel A.
Slide 24: Board of Directors
Board of Directors Jamieson Bondarenko, CFA, CMT William V. Williams, MD, FACP Chairman of the Board President & CEO, Director ▪ Eight Capital, Dundee Securities, Wellington ▪ Incyte, GlaxoSmithKline West Capital Markets and HSBC Securities Vaughn Embro-Pantalony, MBA, FCPA, FCMA, Jane Gross, PhD CD
Slide 25: Capitalization Structure
Capitalization Structure* Stock Symbols: Nasdaq: BCTX, BCTXL TSX: BCT Share Price: US$4.16 Shares Outstanding: 8.7M Market Cap: US$36M Options (US$33.06 WAEP): 337k Warrants (US$16.22 WAEP): 7.2M (*) as of Sept 28, 2026 25
Slide 26: Investment Highlights
Investment Highlights ▪ Bria-IMT + CPI: Pivotal phase 3 study underway in metastatic breast cancer ▪ ~2-fold increase in survival in Phase 2 compared to comparable patients in the literature ▪ Phase 3 interim analysis expected in 2026 ▪ Bria-OTS/OTS+ : Ongoing phase 1/2a studies for Bria-BRES and Br
Slide 27: Thank-you!
Developing Novel Therapeutics to Destroy Cancer Thank-you! 27
BriaCell Therapeutics — Investor Presentation (September 2026) on 6ix